VAXiCAN shared a post on X:
“Dr Łukasz Rąbalski, Founder and CEO of VAXICAN, delivered a talk on:
‘Development of an enveloped virus-like particle (eVLP) platform for therapeutic cancer immunovaccines: production scale-up and preclinical characterization of an HER2-targeting candidate’- University of Gdansk.”
Matt Sagan, Founder, Managing Partner, and CEO of MoD Partners, as well as Co-Founder, Chief Growth & Strategy Officer, and Board Member at VAXiCAN, shared this post, adding:
“Great presentation from Łukasz Rąbalski of VAXICAN at International Centre for Cancer Vaccine Science in Gdansk.
Preliminary data showing strong eVLP uptake to anti-tumor immunity with dual effector arms and cold hot tumor conversion Comprehensive preclinical assesment validates biophysical data, invitro safety, immunogenicity and stability.
Supported by Agencja Badań Medycznych and all the investors.
Great base to move forward with all preclinical programs.”
Other articles featuring Matt Sagan on OncoDaily.